Bürkert invests in start-up Green Elephant Biotech
Working together for a sustainable future
Bürkert Fluid Control Systems has taken a stake in Green Elephant Biotech as a strategic investor so the two companies can work together to develop more efficient, flexible and sustainable cell cultivation processes in the pharmaceutical and biotech industries. This partnership should enable more cost-effective production of therapeutics and facilitate access to the latest biopharmaceutical trends.
Family business invests in start-up
As part of a strategic partnership, Bürkert Fluid Control Systems has taken a stake in the Giessen-based start-up Green Elephant Biotech. Together with Bürkert, the start-up is aiming to make cell cultivation processes in the pharmaceutical and biotech industries more efficient, flexible and sustainable so that, for example, life-saving therapeutics can be produced more cost-effectively. The partnership gives Bürkert access to the latest trends and developments in the biopharmaceutical industry, one of the strategic core markets of the fluidics specialist from Ingelfingen. “We believe that Green Elephant Biotech’s innovative cell culture systems have great potential to revolutionise production processes in the industry. This is in line with our corporate vision of bringing solutions for a regenerative economy to the market,” says Bürkert CEO Georg Stawowy.
Green Elephant Biotech was founded in 2021 by Dr Joel Eichmann and Felix Wollenhaupt at the Technische Hochschule Mittelhessen University of Applied Sciences in Giessen. Compared to conventional cell culture vessels, the innovative and patented CellScrew® cell cultivation system enables a hugely increased growth surface for adherent cell cultures with the same volume. Furthermore, the CellScrew® is additively manufactured from polylactide (PLA) using 3D printing.
Founder Felix Wollenhaupt explains: “Conventional cell culture vessels are significantly larger, are single-use items, are thrown away after one use and are often incinerated for regulatory reasons. This produces a lot of CO2. Our CellScrew® is, firstly, made from less raw material, which means less waste in and of itself. Secondly, we use PLA, a biopolymer obtained from plants. This reduces the carbon footprint by around 90 % compared to conventional systems.”
By working with Bürkert as a strong, strategic partner, the founders have access to resources that will enable them to further develop their company. Joel Eichmann adds: “Together with Bürkert, we want to turn the CellScrew® into a fully fledged bioreactor. This requires liquids to be exchanged, gases to be monitored and processes to be regulated. Bürkert has the technical components and expertise to integrate this into a system. Together, we want to develop a cost-effective, reliable and sustainable production platform for the pharmaceutical industry, especially for personalised medicine.”
The green transition forms a key part of the start-up’s vision – as manifested in the Green Elephant metaphor. Supporting large companies in the context of the green transition requires new approaches, courageous company founders and family businesses that want to make their contribution to the regenerative economy.
Other news from the department business & finance
These products might interest you
New
Flexcell Zelldehnungsbioreaktoren für zelluläre Biomechanik-Anwendungen by Dunn
Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 9000 research publications
Biostat STR by Sartorius
Biostat STR Generation 3 Bioreactors
Engineered for Ultimate Upstream Performance
Ambr® 250 HT Consumables by Sartorius
Efficient bioprocesses with single-use bioreactors
Minimise cleaning effort and maximise flexibility for cell and microbial cultures
Ambr® 250 Modular by Sartorius
Mini bioreactors for cell and gene therapies with high scalability
Maximise your process development with reliable single-use vessels
Flexcell Systems by Dunn
Flexcell Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 4000 research publications
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.